Mark Barnes Comments in Bloomberg Law on New Clinical Trial Diversity Requirements

In The News
February 6, 2023

In a Bloomberg Law article, health care partner Mark Barnes commented on new clinical trial diversity requirements that can assist panels charged with ethics reviews of human studies.

All research must pass a review by an ethics panel known as an institutional review board if the study involves human subjects and is either FDA-regulated or federally funded.

Mark expects IRBs would be influenced by guidance that the U.S. Food and Drug Administration would produce on the issue of enhancing opportunities for more equitable enrollment in clinical trials.